Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is the streptococcus-triggered subset of pediatric acute-onset neuropsychiatric syndrome (PANS). It is defined by the abrupt, dramatic onset or episodic relapsing-remitting exacerbation of obsessive-compulsive disorder and/or a tic disorder in prepubertal children, temporally associated with group A beta-hemolytic streptococcal (GAS) infection and accompanied by additional neuropsychiatric signs such as anxiety, emotional lability, behavioral regression, and choreiform movements. The proposed mechanism is post-streptococcal molecular mimicry, in which antibodies raised against streptococcal antigens cross-react with neuronal targets in the basal ganglia (including dopamine receptors and lysoganglioside), activating calcium/calmodulin-dependent protein kinase II signaling and disrupting cortico-striato-thalamo-cortical circuits. PANDAS overlaps clinically and mechanistically with Sydenham chorea. Both the diagnostic construct and the strength of the streptococcal-autoimmune link remain debated, and there is no validated confirmatory biomarker.
Ask a research question about Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections:
name: Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections
creation_date: "2026-07-25T00:00:00Z"
category: Autoimmune
description: >-
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal
infections (PANDAS) is the streptococcus-triggered subset of pediatric
acute-onset neuropsychiatric syndrome (PANS). It is defined by the abrupt,
dramatic onset or episodic relapsing-remitting exacerbation of
obsessive-compulsive disorder and/or a tic disorder in prepubertal children,
temporally
associated with group A beta-hemolytic streptococcal (GAS) infection and
accompanied by additional neuropsychiatric signs such as anxiety, emotional
lability, behavioral regression, and choreiform movements. The proposed
mechanism is post-streptococcal molecular mimicry, in which antibodies raised
against streptococcal antigens cross-react with neuronal targets in the basal
ganglia (including dopamine receptors and lysoganglioside), activating
calcium/calmodulin-dependent protein kinase II signaling and disrupting
cortico-striato-thalamo-cortical circuits. PANDAS overlaps clinically and
mechanistically with Sydenham chorea. Both the diagnostic construct and the
strength of the streptococcal-autoimmune link remain debated, and there is no
validated confirmatory biomarker.
disease_term:
preferred_term: pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections
term:
id: MONDO:0019020
label: PANDAS
parents:
- Pediatric Acute-onset Neuropsychiatric Syndrome
- Autoimmune Disease
- Mental Health Disorder
pathophysiology:
- name: Post-streptococcal molecular mimicry
biological_scale: MOLECULAR
description: >-
In a subset of children, group A streptococcal infection elicits antibodies
that cross-react with neuronal antigens, proposed to reflect molecular
mimicry between streptococcal epitopes and host brain proteins. This is the
defining etiologic feature distinguishing PANDAS from the broader,
trigger-agnostic PANS construct.
downstream:
- target: Anti-neuronal antibody targeting of the basal ganglia
description: >-
Cross-reactive antibodies are modeled upstream of basal ganglia dysfunction
and the acute-onset neuropsychiatric phenotype.
evidence:
- reference: PMID:39325550
reference_title: "Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders"
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Furthermore, the molecular mimicry hypothesis whereby microbes share antigens with host tissues such as the brain and lead to autoimmune sequelae is supported by our data in that microbial antigens were sufficient to remove AAb reactivity with D1R and D2R
explanation: >-
States the molecular mimicry hypothesis and the experimental result that
supports it - microbial antigens competed away autoantibody reactivity
with the dopamine receptors. This is the claim the node makes; the
previous snippet on this node described only sudden-onset OCD and tics and
never mentioned mimicry, antibodies, or cross-reactivity.
- reference: PMID:26657857
reference_title: "Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Group A streptococcal (GAS) infection induces the production of Abs that cross-react with host neuronal proteins, and these anti-GAS mimetic Abs are associated with autoimmune diseases of the CNS.
explanation: >-
States the cross-reactivity between streptococcal-induced antibodies and
host neuronal proteins that the mimicry node asserts.
- reference: PMID:34778136
reference_title: "Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are clinical conditions characterized by the sudden onset of obsessive-compulsive disorder and/or tics, often accompanied by other behavioral symptoms in a group of children with streptococcal infection.
explanation: >-
The full definitional sentence, naming PANDAS as its subject and the
streptococcal association. The earlier quote began mid-clause and dropped
both.
- name: Anti-neuronal antibody targeting of the basal ganglia
biological_scale: MOLECULAR
description: >-
Cross-reactive antibodies are proposed to bind neuronal targets in the basal
ganglia (including dopamine D1/D2 receptors and lysoganglioside GM1) and
activate calcium/calmodulin-dependent protein kinase II (CaMKII) signaling,
disrupting cortico-striato-thalamo-cortical circuits and producing
obsessive-compulsive symptoms, tics, and choreiform movements. This
mechanism is shared with Sydenham chorea.
downstream:
- target: Acute-onset obsessive-compulsive behavior
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
Basal ganglia autoantibody activity is modeled upstream of the abrupt
obsessive-compulsive phenotype.
- target: Tics
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
The tic phenotype, which the diagnostic criteria treat as the alternative
cardinal presentation to OCD.
- target: Anxiety
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
One of the associated neuropsychiatric symptoms accompanying flares.
- target: Emotional lability
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
A second associated neuropsychiatric symptom from the same process.
evidence:
- reference: PMID:39325550
reference_title: "Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders"
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
GAS-induced cross-reactive AAbs promote autoimmune encephalitis of the
basal ganglia, a region of high dopamine receptor density
explanation: >-
Supports GAS-induced cross-reactive autoantibodies targeting dopamine
receptors in the basal ganglia as a mechanism of post-streptococcal
neuropsychiatric sequelae.
- reference: PMID:39325550
reference_title: "Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Group A streptococcal (GAS) infections can cause autoimmune sequelae
characterized by movement disorders, such as Sydenham chorea, and
neuropsychiatric disorders
explanation: >-
Establishes the shared post-streptococcal autoimmune basis of Sydenham
chorea and related neuropsychiatric disorders.
- name: Th17-mediated CNS entry and blood-brain barrier breakdown
biological_scale: CELLULAR
description: >-
A second, cellular arm of the post-streptococcal mechanism, separate from
the humoral one. Repeated intranasal group A streptococcal challenge in mice
drives streptococcus-specific Th17 cells from nasal-associated lymphoid
tissue into the brain, with blood-brain barrier breakdown, serum IgG
deposition, microglial activation and loss of excitatory synaptic proteins -
and with no viable bacteria recoverable from CNS tissue. The affected
regions are the olfactory bulb and its direct projection targets. This
offers a route by which the cross-reactive antibodies of the mimicry node
could reach their neuronal targets at all.
downstream:
- target: Anti-neuronal antibody targeting of the basal ganglia
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
Barrier breakdown and IgG deposition are modeled upstream of antibody
engagement with neuronal targets, since intact barrier function would
otherwise limit access. The intermediates are unstated because the mouse
work does not trace the route to the basal ganglia specifically.
evidence:
- reference: PMID:26657857
reference_title: "Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Intranasal challenge of repeatedly GAS-inoculated mice promoted migration of GAS-specific Th17 cells from NALT into the brain, BBB breakdown, serum IgG deposition, microglial activation, and loss of excitatory synaptic proteins under conditions in which no viable bacteria were detected in CNS tissue.
explanation: >-
The experimental result this node describes, in mice.
notes: >-
Entirely mouse-derived. No cited source demonstrates Th17 CNS infiltration
or barrier breakdown in a child with PANDAS, so this node states a proposed
route rather than an observed one, and its downstream edge is marked
indirect with unknown intermediates for that reason. It is included because
the humoral arm on its own does not explain how antibodies reach neurons.
phenotypes:
- name: Acute-onset obsessive-compulsive behavior
description: >-
Abrupt onset or episodic relapsing exacerbation of obsessions and
compulsions is a cardinal feature.
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
sudden-onset neuropsychiatric symptoms in children, which can include
obsessive-compulsive disorder (OCD), tics, anxiety, emotional instability,
and cognitive difficulties
explanation: >-
The 2024 Delphi consensus characterizes PANDAS/PANS by sudden-onset OCD,
tics, and associated neuropsychiatric symptoms.
phenotype_term:
preferred_term: Compulsive behaviors
term:
id: HP:0000722
label: Compulsive behaviors
temporality: RECURRENT
- name: Tics
description: >-
Motor and/or vocal tics, of abrupt or episodic onset, are a cardinal
feature and may co-occur with OCD.
phenotype_term:
preferred_term: Tics
term:
id: HP:0100033
label: Tics
temporality: RECURRENT
evidence:
- reference: PMID:34778136
reference_title: "Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are clinical conditions characterized by the sudden onset of obsessive-compulsive disorder and/or tics, often accompanied by other behavioral symptoms in a group of children with streptococcal infection.
explanation: >-
Names tics as one of the two cardinal sudden-onset presentations.
- name: Anxiety
description: >-
Acute anxiety, frequently including separation anxiety, is a common
associated neuropsychiatric symptom.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
sudden-onset neuropsychiatric symptoms in children, which can include
obsessive-compulsive disorder (OCD), tics, anxiety, emotional instability,
and cognitive difficulties
explanation: >-
Names anxiety among the associated sudden-onset symptoms.
- name: Emotional lability
description: >-
Emotional lability and mood swings frequently accompany symptom flares.
phenotype_term:
preferred_term: Emotional lability
term:
id: HP:0000712
label: Emotional lability
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
sudden-onset neuropsychiatric symptoms in children, which can include
obsessive-compulsive disorder (OCD), tics, anxiety, emotional instability,
and cognitive difficulties
explanation: >-
Names emotional instability, which is what this phenotype records.
- name: Enuresis
description: >-
New-onset urinary frequency or enuresis is a recognized associated somatic
sign.
phenotype_term:
preferred_term: Enuresis
term:
id: HP:0000805
label: Enuresis
notes: >-
Deliberately not wired to the antibody node, for the same reason as the
PANS entry: it is listed among the supporting somatic signs, and no cited
source connects it to basal ganglia autoantibody activity.
diagnosis:
- name: Clinical diagnostic criteria
presence: >-
Diagnosis is clinical, requiring presence of OCD and/or a tic disorder with
prepubertal onset, an abrupt onset or episodic relapsing-remitting course,
temporal association with group A streptococcal infection, and associated
neurological abnormalities such as choreiform movements.
diagnosis_term:
preferred_term: clinical diagnosis
term:
id: NCIT:C124351
label: Clinical Evaluation
evidence:
- reference: PMID:25325534
reference_title: "Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
the larger category of pediatric acute-onset neuropsychiatric syndrome
(PANS)
explanation: >-
The PANS Consensus Conference frames PANDAS as a streptococcus-associated
subset within the larger PANS category, informing the clinical diagnostic
approach.
animal_models:
- name: GAS-antigen-exposed Lewis rat model of streptococcal neuropsychiatric disease
species: Rat
genotype: wild-type
background: Male Lewis rat
publication: PMID:22534626
description: >-
Male Lewis rats immunised with group A streptococcal antigen develop
compulsive-like grooming and motor abnormalities, striatal, thalamic and
frontal-cortical IgG deposition, and altered dopamine and glutamate levels.
Serum IgG reacts with tubulin and raises CaMKII signalling in neuronal
cells, and the behavioural abnormalities respond to a D2 blocker and to an
SSRI. It was built as a model of Sydenham chorea and related
streptococcus-associated neuropsychiatric disorders.
modeled_mechanisms:
- target: Anti-neuronal antibody targeting of the basal ganglia
relationship: RECAPITULATES
fidelity: MODERATE
model_scale: ORGANISM
description: >-
Reproduces the core claim of this node in an animal: streptococcal
exposure alone produces antibody deposition in basal ganglia and related
structures, with the CaMKII signalling and D1/D2 receptor autoantibodies
the node describes, and with behavioural consequences.
limitations: >-
Immunisation with streptococcal antigen plus adjuvant is not natural
infection, and a rat's induced grooming is a behavioural analogue of
compulsion rather than obsessive-compulsive disorder. The model was
developed for Sydenham chorea, which shares the mechanism but not the
PANDAS diagnostic criteria, and it says nothing about the prepubertal
onset or streptococcal temporal association those criteria require.
evidence:
- reference: PMID:22534626
reference_title: "Behavioral, Pharmacological, and Immunological Abnormalities after Streptococcal Exposure: A Novel Rat Model of Sydenham Chorea and Related Neuropsychiatric Disorders"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Streptococcal exposure resulted in antibody deposition in the striatum, thalamus, and frontal cortex, and concomitant alterations in dopamine and glutamate levels in cortex and basal ganglia, consistent with the known pathophysiology of SC and related neuropsychiatric disorders.
explanation: >-
The antibody deposition and neurotransmitter changes that make this
model informative for the antibody node.
- reference: PMID:22534626
reference_title: "Behavioral, Pharmacological, and Immunological Abnormalities after Streptococcal Exposure: A Novel Rat Model of Sydenham Chorea and Related Neuropsychiatric Disorders"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Male Lewis rats exposed to GAS antigen exhibited motor symptoms (impaired food manipulation and beam walking) and compulsive behavior (increased induced-grooming).
explanation: >-
The behavioural readout produced by streptococcal antigen exposure.
- reference: PMID:22534626
reference_title: "Behavioral, Pharmacological, and Immunological Abnormalities after Streptococcal Exposure: A Novel Rat Model of Sydenham Chorea and Related Neuropsychiatric Disorders"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
These symptoms were alleviated by the D2 blocker haloperidol and the selective serotonin reuptake inhibitor paroxetine, respectively, drugs that are used to treat motor symptoms and compulsions in streptococcal-related neuropsychiatric disorders.
explanation: >-
Pharmacological rescue with agents used clinically in this disease
family, which is what raises the model above a phenotypic resemblance.
treatments:
- name: Anti-streptococcal Antibiotic Therapy
description: >-
Eradicating the group A streptococcal infection is the first therapeutic
priority, with an initial 6-10 day course of amoxicillin, penicillin, or a
cephalosporin where allergy is documented.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Antibiotic Therapy
term:
id: NCIT:C15620
label: Antibiotic Therapy
therapeutic_agent:
- preferred_term: amoxicillin
term:
id: CHEBI:2676
label: amoxicillin
target_mechanisms:
- target: Post-streptococcal molecular mimicry
description: >-
Removing the antigenic stimulus is the point at which antibiotic treatment
acts on this entry's mechanism.
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Concerning GAS infections, an initial course with an effective treatment on GAS (amoxicillin, penicillin, cephalosporin in case of documented allergic reactions) for 6-10 days is recommended
explanation: >-
The consensus regimen for the streptococcal trigger.
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Neuropsychiatric symptoms (especially the obsessive-compulsive ones) improve rapidly with an effective antibiotic treatment in eradicating the infection.
explanation: >-
States the claimed neuropsychiatric effect of eradicating the infection.
- name: Antibiotic Prophylaxis
description: >-
Long-term antibiotic prophylaxis is considered for severe PANDAS or repeated
streptococcus-associated exacerbations, but the consensus is explicit that
its effectiveness is not established and that no dosing schedule has been
validated.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Antibiotic Prophylaxis
term:
id: NCIT:C51993
label: Antibiotic Prophylaxis
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Antibiotic therapies in children with PANDAS are effective in eradicating the causative pathogen during the active phase of the infection, but further evidence is needed to determine its effectiveness in terms of prophylaxis.
explanation: >-
Records both the acute-phase effectiveness and the explicit uncertainty
about prophylaxis, which is why this is a separate record from the acute
antibiotic one.
- name: Cognitive Behavioral Therapy and SSRI
description: >-
Psychotherapeutic management, principally cognitive-behavioral therapy with
low-dose SSRIs for the obsessive-compulsive symptoms.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: Cognitive Behavior Therapy
term:
id: NCIT:C64345
label: Cognitive Behavior Therapy
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
CBT and other forms of psychotherapy have an important role especially in reducing the obsessive-compulsive neuro-psychiatric symptoms in patients with PANS or PANDAS.
explanation: >-
States the role of CBT in reducing the obsessive-compulsive symptoms.
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
the psychiatric symptoms in these patients are usually treated with CBT and that the OCD generally respond well to SSRI at small doses
explanation: >-
Names low-dose SSRIs for the obsessive-compulsive symptoms.
differential_diagnoses:
- name: Sydenham chorea
description: >-
The other post-streptococcal neuropsychiatric disorder, sharing the
anti-basal-ganglia antibody mechanism modeled in this entry.
distinguishing_features:
- >-
Sydenham chorea presents with chorea and is a major criterion of acute
rheumatic fever; PANDAS is defined by obsessive-compulsive symptoms and/or
tics without requiring chorea or rheumatic fever. The dopamine-receptor
autoantibody study cited here separates the two by D1R versus D2R
reactivity rather than by mechanism class.
- name: Tourette Syndrome
description: >-
A primary chronic tic disorder of childhood.
distinguishing_features:
- >-
Gradual onset and a chronic waxing-and-waning course without a temporal
streptococcal association, where PANDAS requires abrupt or episodic onset
linked in time to group A streptococcal infection.
- name: Pediatric Acute-onset Neuropsychiatric Syndrome
description: >-
The trigger-agnostic parent construct, of which this entry is the
streptococcus-defined subset.
distinguishing_features:
- >-
PANS requires neither a demonstrated streptococcal trigger nor prepubertal
onset, and admits restricted eating as a cardinal presentation; PANDAS
requires the streptococcal temporal association and prepubertal onset, and
is defined on obsessive-compulsive symptoms and/or tics.
discussions:
- discussion_id: pandas_construct_contested
kind: CONTROVERSY
status: OPEN
attaches_to:
- pathophysiology#Post-streptococcal molecular mimicry
prompt: >-
Is the streptococcal-autoimmune link specific enough to define a disease
entity, or does PANDAS describe a temporal coincidence?
rationale: >-
The mechanism curated here rests on cross-reactive autoantibodies, and the
supporting work is strongest in Sydenham chorea and in animal and in vitro
systems. No cited source provides a confirmatory biomarker that separates a
child with PANDAS from one with a primary tic or obsessive-compulsive
disorder who happened to have a recent streptococcal infection. The
narrative review cited here records that the diagnosis has been
controversial since it was first defined in 1998. This is recorded as a
structured controversy rather than left in prose because it bounds every
causal claim in the entry.
notes: >-
Three things about this entry are deliberate.
First, **the mimicry node's evidence was replaced rather than supplemented.**
It previously rested on a sentence describing sudden-onset OCD and tics, which
says nothing about mimicry, antibodies, or cross-reactivity. The node now
cites the experiment that supports the hypothesis directly - microbial
antigens competing away autoantibody reactivity with D1R and D2R - plus the
cross-reactivity statement from the Th17 paper.
Second, **the Th17 node is entirely mouse-derived and says so.** It is
included because the humoral arm alone does not explain how cross-reactive
antibodies reach neurons, and the barrier-breakdown result is the only cited
account of that step. Its own `notes` records that no human demonstration
exists.
Third, **`Enuresis` is deliberately unwired**, as in the PANS entry.
Fourth, **choreiform movements are named in three places but deliberately not
bound as a phenotype.** `HP:0002072` Chorea is frank chorea, and this entry
distinguishes the two explicitly: the choreiform movements of PANDAS are
low-amplitude piano-playing movements elicited on examination, which is what
the diagnostic criteria mean, not the involuntary chorea of Sydenham chorea
that the differential turns on. Binding `HP:0002072` would collapse the
distinction the entry exists to draw. `runoak -i ols:hp search "choreiform"`
returns exactly two terms, `HP:0007166` Paroxysmal dyskinesia and
`HP:0002072` Chorea, neither of which is the elicited sign; `"piano playing
movements"` returns nothing. So the sign is left unbound rather than
approximated to a term that would assert frank chorea.
Two references were repaired in the review round rather than dropped. This
entry originally cited `DOI:10.1038/npp.2012.56` and `DOI:10.1172/JCI80792`,
both of which cache with `content_type: unavailable` and an empty body, so
nothing could ever have been quoted from either - which is why the review
found them listed but unused. Both resolve to PubMed records with full text
(`PMID:22534626` and `PMID:26657857`) and are now cited in that form, one as
the `animal_models` entry and one as the Th17 node.
references:
- reference: PMID:34778136
title: "Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data"
findings: []
- reference: PMID:39325550
title: "Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders"
findings: []
- reference: PMID:39512340
title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
findings: []
- reference: PMID:25325534
title: "Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference."
findings: []
- reference: PMID:22534626
title: "Behavioral, Pharmacological, and Immunological Abnormalities after Streptococcal Exposure: A Novel Rat Model of Sydenham Chorea and Related Neuropsychiatric Disorders"
findings: []
- reference: PMID:26657857
title: "Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells"
findings: []
- reference: PMID:30996598
title: "PANDAS/PANS in childhood: Controversies and evidence"
findings: []
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Create: PANDAS, with the PR #7458 review round folded in · 2026-09-20T23:53:28Z · View source
Creation of the PANDAS entry, plus the review round on PR #7458. One record, because no history record was ever added for the original creation (blocking item 6 of the review). Original curation: Falcon deep-research-sourced, MONDO:0019020, curated as the streptococcus-defined subset of PANS with the boundary held consistently across both entries and the grouping. Item 4, a node whose snippet did not carry its claim. The node "Post-streptococcal molecular mimicry" rested on a quote reading only "are clinical conditions characterized by the sudden onset of obsessive-compulsive disorder and/or tics" - which mentions neither mimicry, nor antibodies, nor cross-reactivity, and whose explanation bridged the gap with the curator's own inference. Replaced with two snippets that state the claim directly: the molecular-mimicry result from PMID:39325550, where microbial antigens were sufficient to compete away autoantibody reactivity with D1R and D2R, and the cross-reactivity statement from PMID:26657857. The original definitional sentence is retained on the same node in its untruncated form. Item 3, a mid-clause truncation. That same quote began after the sentence's subject and stopped before the trailing "in a group of children with streptococcal infection", dropping both the entity being defined and the streptococcal association. Replaced with the complete sentence from PMID:34778136. Item 5, a dangling causal edge. The target "Acute-onset OCD and tics" matched no node or phenotype name. Split into four resolving edges - obsessive-compulsive behavior, tics, anxiety, emotional lability - each INDIRECT_UNKNOWN_INTERMEDIATES. Item 2, no treatments block. Added three records sourced from the cached full text of the 2024 Delphi consensus PMID:39512340: anti-streptococcal antibiotic therapy (with a target_mechanisms link to the mimicry node, since eradicating the antigen is where the drug meets this entry's mechanism), antibiotic prophylaxis as a separate record because the consensus is explicit that acute-phase effectiveness and prophylactic effectiveness are different questions and the latter is unestablished, and CBT with SSRIs. All snippets extracted programmatically from the cache, which is a PDF-derived text with ligature corruption in places. Two references that the review found listed but never used turned out to be unusable, and were repaired rather than consumed as suggested. DOI:10.1038/npp.2012.56 (rat model of Sydenham chorea) and DOI:10.1172/JCI80792 (GAS intranasal infection, Th17 CNS infiltration) both cache with content_type unavailable and an empty body - nothing could have been quoted from either, which is the likely reason they were left uncited in the first place. Both resolve to PubMed records carrying full text, PMID:22534626 and PMID:26657857, and both are now consumed: - PMID:22534626 became an animal_models entry, the GAS-antigen-exposed male Lewis rat, with a modeled_mechanisms link to the antibody node (RECAPITULATES, MODERATE fidelity, model_scale ORGANISM) and three MODEL_ORGANISM evidence items covering the antibody deposition, the behavioural readout, and the pharmacological rescue. Its limitations record that immunisation with antigen plus adjuvant is not natural infection, that induced grooming is an analogue of compulsion rather than OCD, and that the model was built for Sydenham chorea, which shares the mechanism but not the PANDAS criteria. This is the entry's first MODEL_ORGANISM evidence, which the review noted neither entry had. - PMID:26657857 became a new pathophysiology node, "Th17-mediated CNS entry and blood-brain barrier breakdown", wired upstream of the antibody node. The humoral arm alone does not explain how cross-reactive antibodies reach neurons, and this is the only cited account of that step. The node's notes record that it is entirely mouse-derived and that no human demonstration exists, which is why its downstream edge is indirect with unstated intermediates. Suggestions taken: temporality RECURRENT on the OCD and tic phenotypes, capturing the episodic relapsing-remitting course the description already mentioned in prose; evidence added to the previously uncited Tics, Anxiety and Emotional lability phenotypes; NCIT:C124351 Clinical Evaluation in place of NCIT:C15220; differential_diagnoses for Sydenham chorea, Tourette syndrome and PANS itself; a CONTROVERSY discussion rather than a KNOWLEDGE_GAP, because the open question here is whether the construct picks out a disease entity at all rather than a missing measurement; biological_scale on all three nodes. Enuresis is deliberately unwired for the same reason as in the PANS entry, recorded on the phenotype. Validation: just validate passes with 19/19 snippets verified, up from 5/5.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
PANDAS is a proposed pediatric, post-infectious neuropsychiatric syndrome characterized by abrupt-onset obsessive-compulsive disorder (OCD) and/or tics, an episodic course, and a temporal association with group A streptococcal (GAS; Streptococcus pyogenes) infection. It is generally treated as a streptococcus-associated subset of pediatric acute-onset neuropsychiatric syndrome (PANS). The construct remains controversial: the clinical phenotype is recognized, but a uniquely autoimmune etiology, reliable GAS–flare relationship, and validated diagnostic biomarker have not been established in all affected children. The 2024 Delphi consensus therefore describes PANDAS as a clinical diagnosis requiring careful exclusion of neurologic, psychiatric, infectious, metabolic, and systemic autoimmune alternatives. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 1-2, wilbur2019pandaspansinchildhood pages 1-1, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16)
The best-supported routine interventions are evidence-based OCD/tic care—especially cognitive-behavioral therapy with exposure and response prevention (CBT/ERP), cautious use of selective serotonin-reuptake inhibitors (SSRIs), and standard antibiotic treatment of documented active GAS infection. Long-term antibiotic prophylaxis, corticosteroids, intravenous immunoglobulin (IVIG), therapeutic plasma exchange (TPE), and other immunotherapies have inconsistent or low-certainty evidence and should not be regarded as universally established treatment. Tonsillectomy is not supported as PANDAS therapy. (wilbur2019pandaspansinchildhood pages 3-4, wilbur2019pandaspansinchildhood pages 4-4, wilbur2019pandaspansinchildhood pages 5-6, wilbur2019pandaspansinchildhood pages 4-5)
The table below summarizes the evidence hierarchy.
| Domain | Best-supported finding | Evidence type/sample | Confidence/limitation |
|---|---|---|---|
| Definition/diagnosis | PANDAS is best understood as a clinical syndrome within the broader PANS construct: abrupt onset OCD and/or tics, childhood onset (3 years to puberty), episodic dramatic exacerbations, temporal association with GAS infection, and neurologic abnormalities such as motor hyperactivity or choreiform movements. No definitive confirmatory test exists. Established practice: clinical diagnosis after excluding alternative neurologic/psychiatric disease. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, grandinetti2024pediatricacuteonsetneuropsychiatric pages 1-2, wilbur2019pandaspansinchildhood pages 1-1) | 2024 Delphi consensus; prior review of working definitions | Moderate for use as current clinical framework; low-to-moderate for nosologic certainty because autoimmune causality remains debated. |
| Epidemiology | Male predominance is repeatedly reported: ~59.9% male in a 2022 systematic review and ~65% male in survey/cross-sectional data; male:female ratio reported as 3.33:1. Typical onset is prepubertal, around 6.3 years for tics and 7.4 years for OCD; children 5-12 years appear most susceptible. True incidence/prevalence remain uncertain and likely undermeasured. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 3-4, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16) | Consensus synthesis of cross-sectional/survey/systematic-review data | Moderate for age/sex pattern; low for population incidence/prevalence due to lack of robust population-based studies. |
| Pathophysiology | Leading hypothesis: GAS triggers molecular mimicry and post-infectious neuroimmune responses. Human/in vitro data show PANDAS-associated sera/monoclonal antibodies can enhance dopamine D1 receptor signaling; D1R autoantibodies discriminated PANDAS/PANS cohorts from controls with ~72%, 93%, and 79.5% accuracy in separate cohorts, whereas D2R more strongly characterized Sydenham chorea. Proposed chain: recurrent GAS -> anti-GAS/anti-neuronal immunity -> dopaminergic signaling changes and basal-ganglia inflammation. (menendez2024dopaminereceptorautoantibody pages 1-2, menendez2024dopaminereceptorautoantibody pages 4-5, grandinetti2024pediatricacuteonsetneuropsychiatric pages 3-4) | Human serum/monoclonal antibody study; consensus review | Moderate for biologic plausibility; low-to-moderate for direct causality in routine patients because biomarkers are not universally validated and conflict-of-interest concerns exist in parts of the biomarker literature. |
| Biomarkers | No circulating biomarker or autoantibody panel is currently pathognomonic. The Cunningham/Moleculera panel may provide auxiliary information, but sensitivity/specificity and clinical utility remain unclear. MRI/EEG abnormalities can occur but are not diagnostic. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 8-9, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, wilbur2019pandaspansinchildhood pages 5-6) | Consensus statement; review evidence | High that no validated diagnostic biomarker exists; major limitation is poor standardization and lack of prospective validation. |
| Prognosis | Course is usually relapsing-remitting, but a substantial minority have chronic/progressive illness. In a Swedish PANS follow-up (n=34, median 3.3 years), 2 remitted, 20 were relapsing-remitting, and 12 had chronic-static/progressive course. Consensus synthesis states roughly one-third chronic-progressive and two-thirds relapsing-remitting; OCD (62%) and tics (50%) were common follow-up symptoms. In a prior PANDAS longitudinal cohort, 72% had at least one exacerbation, 12% had clinically significant OCD at follow-up, and 9% had chronic-progressive course. (gromark2022atwotofiveyear pages 1-2, grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13) | Longitudinal cohort studies; consensus synthesis | Moderate because follow-up data exist but sample sizes are small and combine PANS/PANDAS constructs. |
| Acute GAS treatment | When active GAS infection is documented, standard anti-streptococcal treatment is recommended; this is the most established infectious-disease intervention. Small prospective data cited in consensus report suggest OCD symptoms may rapidly improve after eradication therapy in new-onset PANDAS, but evidence base is small. Children with psychiatric symptoms but no evidence of GAS should not routinely receive antibiotics. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13, wilbur2019pandaspansinchildhood pages 5-6) | Consensus/guideline-style recommendations; small prospective studies | Moderate for treating documented GAS infection; low for expecting consistent neuropsychiatric remission from antibiotics alone. |
| CBT/SSRIs | Best-supported symptomatic therapy is standard OCD care: CBT/ERP and SSRIs. Response rates appear similar to non-PANDAS pediatric OCD. Small PANDAS CBT data: n=7 with symptom improvement; 3/6 in remission at 3 months. Survey/retrospective evidence and consensus place CBT/SSRIs as first-line symptomatic treatment. (wilbur2019pandaspansinchildhood pages 3-4, wilbur2019pandaspansinchildhood pages 5-6, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16) | Small interventional study; reviews/consensus | Moderate for use in practice because evidence is extrapolated from pediatric OCD and supported by small PANDAS studies. |
| Prophylactic antibiotics | Evidence is inconsistent and insufficient for routine prophylaxis. A randomized placebo-controlled crossover trial (n=37) found penicillin prophylaxis did not reduce exacerbation rates or tic/OCD severity; a noncontrolled 12-month study (n=23) reported 96% fewer GAS infections and 61% fewer neuropsychiatric exacerbations. Reviews and clinical guidance do not recommend routine prophylactic antibiotics. (wilbur2019pandaspansinchildhood pages 3-4, wilbur2019pandaspansinchildhood pages 5-6, gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20) | One randomized trial; one uncontrolled study; reviews | Low-to-moderate because results conflict and better-controlled data are lacking. |
| Steroids/NSAIDs | Anti-inflammatory therapy is used selectively, not as universal standard care. Retrospective evidence suggests corticosteroids shortened flares by ~3.5 weeks; consensus notes evidence for NSAIDs/steroids is scarce and they should be individualized, generally under specialist oversight. (wilbur2019pandaspansinchildhood pages 3-4, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20) | Retrospective study; expert consensus | Low due to nonrandomized evidence and uncertain patient selection. |
| IVIG/PLEX | Immunomodulation remains investigational/specialist care. Earlier controlled trial data suggested improvement with IVIG or plasma exchange in severe cases, but a later randomized double-blind IVIG trial in 35 children found no significant difference vs placebo at 6 weeks; longer-term improvements occurred across groups and may reflect natural history. Open-label studies in PANS show improvement (e.g., 10-child 2022 trial; 2024 study of 10 boys with improved psychometric scores and reduced pro-inflammatory monocytes), but these do not resolve efficacy. PLEX retrospective severe-PANS series reported ~65% improvement at 6 months and 78% at longer follow-up. (wilbur2019pandaspansinchildhood pages 4-4, wilbur2019pandaspansinchildhood pages 4-5, NCT01281969 chunk 1, gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20) | Randomized trials plus open-label/retrospective studies | Low-to-moderate for efficacy; strongest limitation is placebo response, spontaneous improvement, small samples, and heterogeneity. |
| Tonsillectomy | Not supported as effective treatment. Larger retrospective/prospective studies found no meaningful differences in OCD/tic severity, GAS titers, or remission between surgery and no surgery; consensus and reviews do not recommend routine tonsillectomy/adenoidectomy for PANDAS. (wilbur2019pandaspansinchildhood pages 4-4, wilbur2019pandaspansinchildhood pages 5-6, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16) | Retrospective and prospective observational studies | Moderate for concluding lack of supportive evidence; absence of randomized trials remains a limitation. |
| Genetics/familial predisposition | No monogenic cause is established. Family autoimmunity is enriched: ~20% of first-degree relatives had at least one serious autoimmune diagnosis; rheumatic fever history was reported in 3% of mothers, 1% of fathers, and 14% of grandparents in one survey synthesis. Exploratory WES in severe PANS identified variants in 11 genes (including PLCG2, NLRC4, CACNA1B, SHANK3, GRIN2A, RAG1, SYNGAP1), but these are susceptibility candidates, not diagnostic PANDAS genes. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 3-4, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16) | Family-history surveys; exploratory WES in severe PANS | Low-to-moderate for susceptibility signal; low for clinical genetic testing utility in PANDAS today. |
| Animal models | Recurrent intranasal GAS mouse models support a mechanistic neuroimmune pathway: GAS-specific Th17 cells from NALT/tonsil-associated immunity can enter the brain, with BBB breakdown, IgG deposition, microglial activation, and loss of excitatory synaptic proteins in the absence of viable CNS bacteria. Important limitation: pathology localized strongly to olfactory-connected regions, with no extensive basal ganglia BBB damage observed, so model recapitulation is incomplete. (dileepan2016groupastreptococcus pages 1-2, dileepan2016groupastreptococcus pages 11-12) | Human tonsil immunology plus recurrent-GAS mouse model | Moderate for biologic plausibility; low-to-moderate for full disease fidelity to human PANDAS. |
Table: This table summarizes the strongest currently available evidence across diagnosis, mechanisms, treatment, prognosis, genetics, and models for PANDAS. It separates routine clinical practice from investigational or hypothesis-driven areas and highlights the main limitations of the evidence base.
The current working PANDAS criteria are:
PANS is broader: it requires abrupt OCD or severely restricted food intake plus acute symptoms in at least two ancillary domains, but does not require GAS. Consequently, not every PANS case is PANDAS, and tics alone satisfy the historical PANDAS framework but not the core PANS criterion. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16)
Direct abstract quote, 2024 consensus: “PANDAS and PANS are broad diagnoses that encompass a range of sudden-onset neuropsychiatric symptoms in children.” The authors also conclude that “more randomized and controlled trials are needed.” Publication: October 2024; DOI/URL: https://doi.org/10.3389/fimmu.2024.1420663. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 1-2)
The information summarized here is aggregated disease-level evidence from cohorts, trials, consensus documents, and mechanistic studies—not individual-patient EHR data.
A recent GAS infection is the defining proposed trigger. GAS can be symptomatic or asymptomatic; therefore, a single positive throat swab may indicate infection or carriage, while a single elevated antistreptolysin-O (ASO) or anti-DNase-B value documents immune exposure but does not establish the date of infection or prove causation of neuropsychiatric symptoms. The hypothesized causal sequence is GAS exposure → adaptive anti-streptococcal immunity → molecular mimicry/cellular inflammation in a susceptible child → altered corticostriatal function → acute OCD/tics. This chain is biologically plausible but incompletely proven in humans. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13, grandinetti2024pediatricacuteonsetneuropsychiatric pages 3-4, dileepan2016groupastreptococcus pages 1-2)
No replicated protective allele, diet, supplement, probiotic, or lifestyle intervention has been shown to prevent PANDAS. The 2024 consensus found no clinical evidence that probiotics prevent relapses. Ordinary infection-control measures and timely guideline-based treatment of confirmed GAS are reasonable, but they have not been proven to prevent the syndrome. The proposed gene–environment model is polygenic/heterogeneous susceptibility plus childhood GAS exposure, rather than Mendelian inheritance. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13)
The hallmark is a change from baseline over approximately 24–48 hours, rather than ordinary gradual development of childhood OCD or tics. Severity ranges from mild impairment to inability to attend school, eat, sleep independently, or perform activities of daily living.
| Phenotype | Characteristics and suggested HPO annotation |
|---|---|
| OCD | Core symptom; abrupt contamination fears, checking, intrusive thoughts, reassurance seeking, or rituals. HP:0000722 Obsessive-compulsive behavior. |
| Motor/vocal tics | Core historical criterion; episodic and fluctuating. HP:0100033 Tics. |
| Choreiform movements | Fine “piano-playing” finger/toe movements may occur; frank chorea requires evaluation for Sydenham chorea. HP:0002072 Chorea. |
| Anxiety/separation anxiety | Frequently acute and disabling. HP:0000739 Anxiety; separation anxiety lacks a sufficiently specific universally used HPO term. |
| Emotional lability/irritability/aggression | Abrupt mood swings, rage, oppositional behavior. HP:0000712 Emotional lability, HP:0000737 Irritability. |
| Behavioral/developmental regression | Baby talk, loss of independence, clinginess. HP:0002376 Developmental regression. |
| Restricted eating | Often contamination, choking, vomiting, or sensory driven; more central to PANS than historical PANDAS. HP:0004395 Malnutrition or HP:0008872 Feeding difficulties where clinically applicable. |
| Cognitive/school decline | Attention, working memory, graphomotor and handwriting deterioration. HP:0007018 Attention deficit, HP:0002354 Memory impairment. |
| Sensory/motor abnormalities | Sensory hypersensitivity, restlessness, clumsiness. HP:0000733 Stereotypic behavior only where appropriate; record the specific sensory modality rather than overgeneralizing. |
| Sleep disturbance | Insomnia, night waking, altered sleep schedule. HP:0100785 Insomnia. |
| Urinary symptoms | Frequency, urgency, and new enuresis. HP:0000017 Nocturnal enuresis, HP:0000015 Bladder dysfunction. |
| Somatic symptoms | Fatigue, pain, headache, and autonomic complaints are reported but nonspecific. HP:0012378 Fatigue, HP:0002315 Headache. |
In a Swedish cohort followed for a median 3.3 years, follow-up symptoms included OCD in 62%, tics in 50%, anxiety and hyperactivity/impulsivity in 35% each, behavioral difficulties in 32%, and sleep disturbance, depression, and fatigue in 29% each. Acute symptoms can severely impair school attendance, family functioning, nutrition, sleep, and independence. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13, gromark2022atwotofiveyear pages 1-2)
There is no established causal PANDAS gene, pathogenic variant class, chromosomal abnormality, inheritance pattern, carrier frequency, or clinically indicated PANDAS gene panel. Therefore, ACMG classification, penetrance, anticipation, mosaicism, founder effects, and variant-specific population frequencies are not applicable at present.
Exploratory exome sequencing in 386 US and 10 European severe-PANS cases reported variants across PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHEK2/CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1. These genes span immune/microglial regulation and neuronal synaptic function. They should be regarded as heterogeneous candidate findings—not validated PANDAS genes and not evidence that variants in these genes caused PANDAS. Approximately 50% of that severe cohort had overlap with a pre-existing neurodevelopmental condition, creating substantial ascertainment and interpretation issues. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 3-4)
No reproducible PANDAS-specific DNA-methylation, histone, chromatin, structural-genomic, or germline-versus-somatic signature is established. WES/WGS/CMA should be reserved for conventional indications such as developmental delay, epilepsy, dysmorphism, intellectual disability, or a strong monogenic-disease suspicion—not used to confirm PANDAS.
The relevant infectious agent is GAS, Streptococcus pyogenes (NCBI Taxonomy: 1314). Pharyngitis, scarlet fever, skin infection, household/classroom exposure, and asymptomatic carriage are possible contexts. Other infections are relevant principally to the broader PANS differential, not to strict PANDAS. No credible association with smoking, alcohol, occupational exposure, radiation, pollution, toxin, exercise, or a particular diet is established.
Psychosocial stress may aggravate symptoms or perpetuate functional impairment but is not a demonstrated primary cause. Gut/oral microbiome and oxidative-stress hypotheses remain exploratory; they do not support commercial microbiome testing or probiotic treatment as established PANDAS care. (matera2025pediatricacuteonsetneuropsychiatric pages 2-3, grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13)
This sequence integrates human serology/in-vitro signaling and animal data; it is not yet a universally demonstrated causal pathway in patients. (menendez2024dopaminereceptorautoantibody pages 1-2, menendez2024dopaminereceptorautoantibody pages 4-5, dileepan2016groupastreptococcus pages 11-12, dileepan2016groupastreptococcus pages 1-2)
Menendez et al., published September 26, 2024 in JCI Insight, found that patient serum antibodies and patient-derived monoclonal antibodies activated D1-receptor G-protein and β-arrestin signaling and enhanced dopamine-mediated signaling. D1R-antibody ROC accuracy for distinguishing PANDAS/PANS from controls was 72% in one cohort, 93% in a well-characterized PANDAS cohort without choreiform movements, and 79.5% in the largest combined cohort. D2R antibodies better characterized Sydenham chorea. These results support biological plausibility but do not by themselves validate a clinical diagnostic assay; the paper also reports a relevant commercial conflict of interest involving an author and Moleculera Biosciences. DOI/URL: https://doi.org/10.1172/jci.insight.164762. (menendez2024dopaminereceptorautoantibody pages 1-2, menendez2024dopaminereceptorautoantibody pages 4-5)
Direct abstract quote: “Our findings suggest that AAb-mediated D1R signaling may contribute to the pathogenesis of neuropsychiatric sequelae.” The wording “may contribute” is important: it does not establish necessity, specificity, or population-wide causality. (menendez2024dopaminereceptorautoantibody pages 1-2)
In recurrent intranasal GAS-exposed mice, GAS-specific Th17 cells migrated from nasal-associated lymphoid tissue into brain regions, accompanied by BBB breakdown, IgG deposition, microglial activation, and loss of excitatory synaptic proteins despite absence of viable bacteria in CNS tissue. Human tonsils from 28 naturally exposed individuals contained GAS-responsive IL-17A-producing CD4 T cells. However, mouse pathology was concentrated in olfactory-connected regions and did not show extensive basal-ganglia BBB damage, limiting fidelity to human PANDAS. Publication: Journal of Clinical Investigation, January 2016; DOI: https://doi.org/10.1172/JCI80792; PMID 26690792. (dileepan2016groupastreptococcus pages 11-12, dileepan2016groupastreptococcus pages 1-2)
Suggested ontology mappings include GO:0006955 immune response, GO:0006954 inflammatory response, GO:0034341 response to interferon-gamma, GO:0071346 cellular response to interferon-gamma, GO:0007165 signal transduction, GO:0007268 chemical synaptic transmission, and GO:0001525 angiogenesis only where directly measured. Relevant cell types are CL:0000899 T-helper 17 cell, CL:0000129 microglial cell, CL:0000115 endothelial cell, CL:0000236 B cell, and dopaminergic neurons. Relevant chemicals include dopamine (CHEBI:18243) and IL-17A as a protein entity rather than a CHEBI chemical.
Current profiling is small-scale rather than diagnostic. Reported findings include inflammatory cytokines, activated myeloid populations, receptor autoantibodies, and imaging changes. No replicated clinical transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, CRISPR-screen, or multi-omic signature can diagnose human PANDAS. A 2024 open-label IVIG study of ten boys found reduced pro-inflammatory monocytes/dendritic cells alongside improved psychiatric scores, but without a control group it cannot distinguish treatment effect from time, regression to the mean, or concomitant care.
The hypothesized primary system is the central nervous system, especially cortico-striato-thalamo-cortical circuitry:
A study of 34 PANS patients showed increased diffusion measures, particularly in deep gray matter including thalamus, basal ganglia, and amygdala. PET research has suggested bilateral caudate neuroinflammation, but imaging is neither specific nor required. No consistent lateralization is established. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 8-9, grandinetti2024pediatricacuteonsetneuropsychiatric pages 3-4)
Suggested terms: UBERON:0002420 basal ganglion, UBERON:0001873 caudate nucleus, UBERON:0001874 putamen, UBERON:0001897 dorsal plus ventral thalamus, UBERON:0001876 amygdala, UBERON:0000120 blood-brain barrier; GO:0005886 plasma membrane, GO:0005911 cell-cell junction, and GO:0045202 synapse.
Onset is pediatric and classically explosive, often progressing from absent/minimal symptoms to maximum severity within 24–48 hours. The subsequent course may be monophasic, relapsing-remitting, chronic-static, or progressive.
In 33 longitudinally followed PANDAS patients, 72% experienced at least one later exacerbation, 12% had clinically significant OCD at follow-up, and 9% had a chronic-progressive course. In the 34-patient Swedish PANS cohort, followed for 2–5 years (median 3.3), two remitted, 20 were relapsing-remitting, and 12 were chronic-static/progressive. Earlier onset and greater baseline impairment characterized the latter group. Complete remission was uncommon, although mean symptom severity and functioning improved. DOI: https://doi.org/10.1007/s10578-021-01135-4; PMID 33547531. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13, gromark2022atwotofiveyear pages 1-2)
There is no validated disease staging system. “Flare” generally means a clinically meaningful exacerbation lasting at least 24 hours, although studies use inconsistent definitions. Early intervention is important for nutrition, suicidality, school loss, family accommodation, and functional decline, but no proven immunologic “critical window” has been established.
PANDAS is best considered multifactorial, with incomplete and undefined susceptibility rather than autosomal dominant, recessive, X-linked, or mitochondrial inheritance. Penetrance, carrier frequency, anticipation, consanguinity effects, and founder mutations are unknown/not applicable.
True incidence and prevalence per 100,000 are not established. Available studies are affected by referral bias, inconsistent criteria, retrospective attribution of GAS exposure, asymptomatic carriage, and overlap with common childhood OCD/tic disorders. Reported male predominance and prepubertal onset are more reliable than any population prevalence estimate. Large-scale prospective population studies are explicitly needed. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 3-4)
No robust ethnic or geographic predilection is established. Apparent geographic variation is likely influenced by GAS circulation, rheumatic-fever epidemiology, referral practices, awareness, and access to specialty clinics.
PANDAS is a diagnosis of pattern plus exclusion, not a positive laboratory diagnosis. Evaluation should document exact onset chronology, prior baseline, OCD/tic phenomenology, functional change, infections and exposures, medication/substance history, neurologic examination, psychiatric risk, family autoimmunity, and developmental history.
During a compatible acute presentation, obtain a properly collected throat swab with rapid antigen/NAAT and/or culture according to local guidelines. Skin culture is appropriate when lesions are present. ASO and anti-DNase-B titers can support preceding GAS exposure, especially when paired acute/convalescent titers rise, but a single titer cannot date infection or establish that GAS caused the psychiatric syndrome. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16)
CBC, metabolic panel, inflammatory markers, thyroid studies, urinalysis, toxicology, autoimmune testing, infectious studies, EEG, MRI, CSF, or metabolic/genetic tests should be clinically targeted, not applied as a universal commercial panel. MRI is most appropriate for focal deficits, severe headache, cognitive decline, psychosis, or suspected encephalitis/vasculitis. EEG may be useful for seizures or encephalopathy; abnormalities were reported in 7/42 PANDAS patients (16%), but are nonspecific. Lumbar puncture is appropriate when altered consciousness, seizures, psychosis, MRI/EEG abnormalities, or autoimmune/infectious encephalitis is suspected. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 8-9)
No pathognomonic antibody exists. The commercial Cunningham/Autoimmune Brain Panel measures anti-D1R, anti-D2R, anti-β-tubulin, anti-lysoganglioside antibodies and CaMKII activity, but pediatric sensitivity, specificity, predictive value, interlaboratory reproducibility, and added clinical utility remain insufficiently established. It should not independently diagnose PANDAS or determine immunotherapy. (wilbur2019pandaspansinchildhood pages 3-4, grandinetti2024pediatricacuteonsetneuropsychiatric pages 8-9)
Priority exclusions include ordinary pediatric OCD, Tourette/chronic tic disorders, anxiety, autism-related rigidity, ADHD, eating disorders/ARFID, medication or stimulant effects, seizures, autoimmune encephalitis including anti-NMDA-receptor encephalitis, Sydenham chorea/acute rheumatic fever, systemic lupus/vasculitis, thyroid disease, Wilson disease, post-infectious encephalopathy, CNS infection, and functional neurologic disorder. Red flags—encephalopathy, seizures, persistent focal deficits, frank chorea, autonomic instability, psychosis, catatonia, fever, or systemic inflammation—require urgent neurologic/infectious/autoimmune evaluation rather than presumptive PANDAS treatment.
There is no asymptomatic population, newborn, prenatal, carrier, or genetic screening program.
PANDAS is not known to shorten life expectancy, and disease-specific mortality rates are unavailable. Its burden is morbidity: severe anxiety/OCD, nutritional compromise, family disruption, school absence, loss of independence, sleep disturbance, and occasionally suicidality or aggression.
Most longitudinally observed children improve, but relapse is common and a minority remain chronically impaired. In the Swedish follow-up, only 15% retained clinically significant OCD despite rare complete remission; 38% received a new neurodevelopmental diagnosis, including ADHD in 26%, autism in 9%, and intellectual disability in 3%. These findings may reflect recognition of pre-existing vulnerabilities rather than PANDAS causing those disorders. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13)
No validated prognostic biomarker exists. Earlier onset, greater baseline impairment, frequent/prolonged flares, comorbid neurodevelopmental disease, and delayed access to effective psychiatric/supportive care may predict a more difficult course, but models require prospective validation.
1. Stabilize and treat the phenotype. Assess suicidality, aggression, dehydration, malnutrition, sleep loss, and inability to function. Use CBT/ERP, family-based behavioral support, school accommodations, and cautious psychiatric pharmacotherapy. Small PANDAS CBT data showed improvement in seven children and remission in 3/6 assessed at three months; broader pediatric OCD evidence is much stronger. SSRIs are generally started low and titrated slowly because behavioral activation is a concern in acutely ill children. (wilbur2019pandaspansinchildhood pages 3-4, wilbur2019pandaspansinchildhood pages 5-6)
Suggested MAXO mappings: MAXO:0000073 cognitive behavioral therapy where available in the implementation ontology; exposure/response prevention should be retained as a textual subtype; medication administration and psychiatric assessment should use the corresponding current MAXO release terms after validation.
2. Treat documented GAS normally. Use guideline-concordant penicillin/amoxicillin or an appropriate alternative based on allergy and local recommendations. Children without evidence of bacterial infection should not automatically receive antibiotics. A small 12-child prospective series reported rapid OCD improvement after GAS eradication, but sample size and lack of controls preclude firm neuropsychiatric efficacy conclusions. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13)
3. Do not assume prophylaxis works. In an n=37 randomized crossover study, penicillin prophylaxis did not reduce exacerbations or tic/OCD severity. An uncontrolled n=23 study reported 96% fewer GAS infections and 61% fewer neuropsychiatric exacerbations on penicillin or azithromycin; without placebo control, causality is uncertain. Routine prophylaxis is therefore not supported, although specialists may individualize decisions in exceptional recurrent, well-documented GAS-linked cases. (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, wilbur2019pandaspansinchildhood pages 3-4)
4. Anti-inflammatory treatment is selective. A retrospective n=98 analysis associated corticosteroids with flares shorter by approximately 3.5 weeks. NSAIDs and short steroid courses are used by specialty programs, but randomized evidence is inadequate. Infection, metabolic, psychiatric, and bone/gastrointestinal risks must be considered. (wilbur2019pandaspansinchildhood pages 3-4)
5. IVIG/TPE remain specialist or investigational interventions. The early n=30 trial found significant one-month improvement with IVIG or TPE versus placebo. A later randomized double-blind study of 35 children found no significant IVIG–placebo response difference at six weeks, despite substantial later improvement across groups. The NIH phase-3 study, NCT01281969, enrolled 48 participants and tested IVIG 2 g/kg over two days against saline with CY-BOCS at six weeks; the registry itself acknowledges insufficient prior evidence. (NCT01281969 chunk 1, wilbur2019pandaspansinchildhood pages 4-4, wilbur2019pandaspansinchildhood pages 4-5)
Open-label evidence remains hypothesis-generating. A 2024 study of ten male PANS patients receiving six IVIG infusions reported improvement on all psychometric scales and reductions in inflammatory monocytes, but lacked a control group. TPE retrospective data in 35 severe patients reported approximately 65% improvement at six months and 78% at longer follow-up. IVIG risks include headache, aseptic meningitis, hemolysis, thrombosis, renal injury, and infusion reactions; TPE requires central access in many children and carries bleeding, infection, hypotension, electrolyte, and line-related risks. (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20)
6. Other immunotherapies and surgery. Rituximab and mycophenolate lack adequate PANDAS trial evidence. Two larger tonsillectomy studies—retrospective n=43 and prospective n=120, including 56 surgical patients—found no meaningful benefit in OCD/tics, GAS titers, or remission. Tonsillectomy should be performed only for ordinary otolaryngologic indications, not solely for PANDAS. (wilbur2019pandaspansinchildhood pages 4-4)
There is no established pharmacogenomic, gene, cell, RNA, or genotype-guided therapy for PANDAS.
Genetic counseling is not routinely required because there is no Mendelian PANDAS genotype. Families should instead receive empiric counseling that familial autoimmune/neuropsychiatric clustering may indicate susceptibility but does not predict deterministic transmission.
No recognized naturally occurring PANDAS-equivalent disease has been established in companion animals, livestock, or wildlife. PANDAS itself is not zoonotic and is not transmitted as a neuropsychiatric syndrome. GAS is a human-adapted pathogen; the relevant cross-species work consists of induced laboratory models rather than natural veterinary disease. Consequently, breed ontology, veterinary carrier frequency, and natural-disease ortholog annotations are not applicable.
Repeated intranasal GAS exposure expands GAS-specific Th17 cells in nasal-associated lymphoid tissue and produces CNS T-cell entry, BBB disruption, IgG deposition, microglial activation, and reduced excitatory synaptic proteins without viable CNS bacteria. It is useful for studying mucosal immunity, IL-17A, neurovascular permeability, and antibody access to brain. Its principal limitation is that injury predominates in olfactory-connected regions rather than showing extensive basal-ganglia pathology, and murine NALT is not anatomically identical to human tonsils/adenoids. (dileepan2016groupastreptococcus pages 11-12, dileepan2016groupastreptococcus pages 1-2)
Lewis rats immunized with GAS antigens develop abnormal movements/repetitive behavior, anti-neuronal antibodies, and antibody deposition in striatum, thalamus, and frontal cortex; some behavioral effects were alleviated by the D2 antagonist haloperidol. Transgenic mouse B cells expressing human Sydenham-chorea monoclonal-antibody variable genes produce antineuronal antibodies targeting dopaminergic basal-ganglia neurons. These models support molecular mimicry and receptor signaling, but more closely overlap Sydenham chorea/basal-ganglia encephalitis than the full heterogeneous PANDAS phenotype. (menendez2024dopaminereceptorautoantibody pages 1-2)
No validated zebrafish, Drosophila, C. elegans, organoid, iPSC, or naturally occurring genetic model recapitulates the complete syndrome.
PANDAS should be represented as a clinically defined, GAS-associated acute-onset pediatric neuropsychiatric syndrome with disputed autoimmune specificity, not as a proven monogenic autoimmune encephalitis. The knowledge base should distinguish:
This cautious classification reflects the authoritative literature’s central conclusion: biologically plausible neuroimmune mechanisms and severely affected patients coexist with small samples, inconsistent criteria, spontaneous fluctuation, referral bias, and few adequately powered randomized trials. (wilbur2019pandaspansinchildhood pages 3-3, grandinetti2024pediatricacuteonsetneuropsychiatric pages 1-2, wilbur2019pandaspansinchildhood pages 5-6, wilbur2019pandaspansinchildhood pages 1-1)
References
(grandinetti2024pediatricacuteonsetneuropsychiatric pages 1-2): Roberto Grandinetti, Nicole Mussi, Simone Pilloni, Greta Ramundo, Angela Miniaci, Emanuela Turco, Benedetta Piccolo, Maria Elena Capra, Roberta Forestiero, Serena Laudisio, Giovanni Boscarino, Laura Pedretti, Martina Menoni, Giuditta Pellino, Silvia Tagliani, Andrea Bergomi, Francesco Antodaro, Maria Cristina Cantù, Maria Teresa Bersini, Sandra Mari, Franco Mazzini, Giacomo Biasucci, Agnese Suppiej, and Susanna Esposito. Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1420663, doi:10.3389/fimmu.2024.1420663. This article has 15 citations and is from a peer-reviewed journal.
(wilbur2019pandaspansinchildhood pages 1-1): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16): Roberto Grandinetti, Nicole Mussi, Simone Pilloni, Greta Ramundo, Angela Miniaci, Emanuela Turco, Benedetta Piccolo, Maria Elena Capra, Roberta Forestiero, Serena Laudisio, Giovanni Boscarino, Laura Pedretti, Martina Menoni, Giuditta Pellino, Silvia Tagliani, Andrea Bergomi, Francesco Antodaro, Maria Cristina Cantù, Maria Teresa Bersini, Sandra Mari, Franco Mazzini, Giacomo Biasucci, Agnese Suppiej, and Susanna Esposito. Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1420663, doi:10.3389/fimmu.2024.1420663. This article has 15 citations and is from a peer-reviewed journal.
(wilbur2019pandaspansinchildhood pages 3-4): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(wilbur2019pandaspansinchildhood pages 4-4): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(wilbur2019pandaspansinchildhood pages 5-6): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(wilbur2019pandaspansinchildhood pages 4-5): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(grandinetti2024pediatricacuteonsetneuropsychiatric pages 3-4): Roberto Grandinetti, Nicole Mussi, Simone Pilloni, Greta Ramundo, Angela Miniaci, Emanuela Turco, Benedetta Piccolo, Maria Elena Capra, Roberta Forestiero, Serena Laudisio, Giovanni Boscarino, Laura Pedretti, Martina Menoni, Giuditta Pellino, Silvia Tagliani, Andrea Bergomi, Francesco Antodaro, Maria Cristina Cantù, Maria Teresa Bersini, Sandra Mari, Franco Mazzini, Giacomo Biasucci, Agnese Suppiej, and Susanna Esposito. Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1420663, doi:10.3389/fimmu.2024.1420663. This article has 15 citations and is from a peer-reviewed journal.
(menendez2024dopaminereceptorautoantibody pages 1-2): Chandra M. Menendez, Jonathan Zuccolo, Susan E. Swedo, Sean Reim, Brian Richmand, Hilla Ben-Pazi, Abraham Kovoor, and Madeleine W. Cunningham. Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders. JCI Insight, Nov 2024. URL: https://doi.org/10.1172/jci.insight.164762, doi:10.1172/jci.insight.164762. This article has 19 citations and is from a domain leading peer-reviewed journal.
(menendez2024dopaminereceptorautoantibody pages 4-5): Chandra M. Menendez, Jonathan Zuccolo, Susan E. Swedo, Sean Reim, Brian Richmand, Hilla Ben-Pazi, Abraham Kovoor, and Madeleine W. Cunningham. Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders. JCI Insight, Nov 2024. URL: https://doi.org/10.1172/jci.insight.164762, doi:10.1172/jci.insight.164762. This article has 19 citations and is from a domain leading peer-reviewed journal.
(grandinetti2024pediatricacuteonsetneuropsychiatric pages 8-9): Roberto Grandinetti, Nicole Mussi, Simone Pilloni, Greta Ramundo, Angela Miniaci, Emanuela Turco, Benedetta Piccolo, Maria Elena Capra, Roberta Forestiero, Serena Laudisio, Giovanni Boscarino, Laura Pedretti, Martina Menoni, Giuditta Pellino, Silvia Tagliani, Andrea Bergomi, Francesco Antodaro, Maria Cristina Cantù, Maria Teresa Bersini, Sandra Mari, Franco Mazzini, Giacomo Biasucci, Agnese Suppiej, and Susanna Esposito. Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1420663, doi:10.3389/fimmu.2024.1420663. This article has 15 citations and is from a peer-reviewed journal.
(gromark2022atwotofiveyear pages 1-2): Caroline Gromark, Eva Hesselmark, Ida Gebel Djupedal, Maria Silverberg, AnnaCarin Horne, Robert A. Harris, Eva Serlachius, and David Mataix-Cols. A two-to-five year follow-up of a pediatric acute-onset neuropsychiatric syndrome cohort. Child Psychiatry and Human Development, 53:354-364, Feb 2022. URL: https://doi.org/10.1007/s10578-021-01135-4, doi:10.1007/s10578-021-01135-4. This article has 58 citations and is from a peer-reviewed journal.
(grandinetti2024pediatricacuteonsetneuropsychiatric pages 12-13): Roberto Grandinetti, Nicole Mussi, Simone Pilloni, Greta Ramundo, Angela Miniaci, Emanuela Turco, Benedetta Piccolo, Maria Elena Capra, Roberta Forestiero, Serena Laudisio, Giovanni Boscarino, Laura Pedretti, Martina Menoni, Giuditta Pellino, Silvia Tagliani, Andrea Bergomi, Francesco Antodaro, Maria Cristina Cantù, Maria Teresa Bersini, Sandra Mari, Franco Mazzini, Giacomo Biasucci, Agnese Suppiej, and Susanna Esposito. Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1420663, doi:10.3389/fimmu.2024.1420663. This article has 15 citations and is from a peer-reviewed journal.
(gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20): Antonella Gagliano, Alessandra Carta, Marcello G Tanca, and Stefano Sotgiu. Pediatric acute-onset neuropsychiatric syndrome: current perspectives. Neuropsychiatric Disease and Treatment, 19:1221-1250, May 2023. URL: https://doi.org/10.2147/ndt.s362202, doi:10.2147/ndt.s362202. This article has 60 citations and is from a peer-reviewed journal.
(NCT01281969 chunk 1): Intravenous Immunoglobulin for PANDAS. National Institute of Mental Health (NIMH). 2011. ClinicalTrials.gov Identifier: NCT01281969
(dileepan2016groupastreptococcus pages 1-2): Thamotharampillai Dileepan, Erica D. Smith, Daniel Knowland, Martin Hsu, Maryann Platt, Peter Bittner-Eddy, Brenda Cohen, Peter Southern, Elizabeth Latimer, Earl Harley, Dritan Agalliu, and P. Patrick Cleary. Group a streptococcus intranasal infection promotes cns infiltration by streptococcal-specific th17 cells. The Journal of clinical investigation, 126 1:303-17, Dec 2016. URL: https://doi.org/10.1172/jci80792, doi:10.1172/jci80792. This article has 173 citations.
(dileepan2016groupastreptococcus pages 11-12): Thamotharampillai Dileepan, Erica D. Smith, Daniel Knowland, Martin Hsu, Maryann Platt, Peter Bittner-Eddy, Brenda Cohen, Peter Southern, Elizabeth Latimer, Earl Harley, Dritan Agalliu, and P. Patrick Cleary. Group a streptococcus intranasal infection promotes cns infiltration by streptococcal-specific th17 cells. The Journal of clinical investigation, 126 1:303-17, Dec 2016. URL: https://doi.org/10.1172/jci80792, doi:10.1172/jci80792. This article has 173 citations.
(matera2025pediatricacuteonsetneuropsychiatric pages 2-3): Mariarosaria Matera, Valentina Biagioli, Maria Teresa Illiceto, Chiara Maria Palazzi, Ilaria Cavecchia, Andrea Manzi, Sebastian Lugli, Laura Pennazzi, Martina Meocci, Fausto Andrea Pedaci, and Alexander Bertuccioli. Pediatric acute-onset neuropsychiatric syndromes and the gut-oral-brain axis: a narrative review of emerging microbiome-immune interactions and therapeutic perspectives. Frontiers in Immunology, Nov 2025. URL: https://doi.org/10.3389/fimmu.2025.1726630, doi:10.3389/fimmu.2025.1726630. This article has 6 citations and is from a peer-reviewed journal.
(NCT01617083 chunk 1): Antibiotic Treatment Trial for the PANDAS/PANS Phenotype. University of South Florida. 2012. ClinicalTrials.gov Identifier: NCT01617083
(wilbur2019pandaspansinchildhood pages 3-3): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.